Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
07:30am, Friday, 03'rd May 2024
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therape
MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
02:31am, Friday, 05'th Apr 2024
Positive safety update released from phase 2 TAMARACK study, using vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer. Updates to interim data from the phase
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
04:30pm, Wednesday, 03'rd Apr 2024
ROCKVILLE, MD, April 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative anti
MacroGenics, Inc. (MGNX) Q4 2023 Earnings Call Transcript
11:30pm, Thursday, 07'th Mar 2024
MacroGenics, Inc. (NASDAQ:MGNX ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Jim Karrels - Senior Vice President and Chief Financial Officer Scott Koenig - President
MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates
06:31pm, Thursday, 07'th Mar 2024
MacroGenics (MGNX) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to earnings of $0.21 per share a year ago.
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
04:01pm, Thursday, 07'th Mar 2024
ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibo
MacroGenics to Participate in Upcoming Investor Conferences
05:48pm, Friday, 01'st Mar 2024
ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-
Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for
11:01am, Thursday, 29'th Feb 2024
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
05:45pm, Tuesday, 27'th Feb 2024
ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based ther
MacroGenics: Evaluating Its Buy Status After A 200% Surge On Prostate Cancer Prospects
10:23pm, Monday, 19'th Feb 2024
MacroGenics' stock has increased by 230% since September due to favorable macroeconomics and interest in antibody-drug conjugates. The company is testing vobramitamab duocarmazine for the treatment of
MacroGenics to Participate in Upcoming Investor Conference
04:30pm, Friday, 02'nd Feb 2024
ROCKVILLE, MD, Feb. 02, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibod
MacroGenics (MGNX) Surges 6.8%: Is This an Indication of Further Gains?
08:21am, Friday, 02'nd Feb 2024
MacroGenics (MGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the
The 3 Most Undervalued Biotech Stocks to Buy in January
04:51pm, Monday, 15'th Jan 2024
Companies within the biotechnology industry are very interesting to investors because they see wild swings in share price following positive or negative news, particularly in the case of small biotech
MacroGenics to Participate in Upcoming Investor Conference
04:30pm, Monday, 08'th Jan 2024
ROCKVILLE, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-b
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
12:03pm, Sunday, 17'th Dec 2023
With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the digital
